As observed in the mouse CRC xenograft model, ESSENCE-high PDX tumors had reduced SLC7A11 and GPX4 expression in the selumetinib treatment group since ERK–ESSENCE–ferroptosis defense signaling is intercepted (Fig. 7F). Here, GPX4 is linked to colorectal carcinoma.